Strong Industry Focus QS Pharma specializes in early-stage pharmaceutical and biopharmaceutical development, offering a comprehensive range of services from NCE screening to commercial manufacturing, positioning it as a key partner for companies seeking integrated development solutions.

Recent Acquisition The company was acquired by Quotient Sciences Limited in February 2017 for $75 million, indicating potential access to additional resources, expanded capabilities, and strategic collaboration opportunities within the drug development ecosystem.

Mid-Size Market Presence With an employee base of 51 to 200 and annual revenues between $10 and $25 million, QS Pharma presents opportunities to engage with a nimble yet established player actively involved in early-phase development projects.

Focused Service Offerings QS Pharma’s dedication to quality and speed, alongside its specialization from preclinical to clinical and commercial phases, makes it a prime candidate for partnerships that require reliable, high-quality manufacturing and development services.

Potential for Expansion Given its strategic positioning within the competitive pharmaceutical development landscape and established focus areas, QS Pharma is well-positioned for growth and could benefit from additional collaborations, technology integrations, or supply chain enhancements.